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Fibronectin Potentiates Topical Erythropoietin-Induced
Wound Repair in Diabetic Mice
Saher Hamed1,2, Yehuda Ullmann1,3, Dana Egozi3, Essam Daod3, Elias Hellou1, Manal Ashkar2,
Amos Gilhar3 and Luc Teot4
Diabetes mellitus disrupts all phases of the wound repair cascade and leads to development of chronic wounds.
We previously showed that topical erythropoietin (EPO) can promote wound repair in diabetic rats. Fibronectin
(FN) has a critical role throughout the process of wound healing, yet it is deficient in wound tissues of diabetic
patients. Therefore, we investigated the effect of topical treatment of both EPO and FN (EPO/FN) on wound
repair in diabetic mice. Full-thickness excisional skin wounds in diabetic and nondiabetic mice were treated
with a cream containing vehicle, EPO, FN, or EPO/FN. We assessed the rate of wound closure, angiogenesis,
apoptosis, and expression of inflammatory cytokines, endothelial nitric oxide synthase (eNOS) and b1-integrin,
in the wound tissues. We also investigated the effect of EPO, FN, and EPO/FN on human dermal microvascular
endothelial cells and fibroblasts cultured on fibrin-coated plates, or in high glucose concentrations. EPO/FN
treatment significantly increased the rate of wound closure and this effect was associated with increased
angiogenesis, increased eNOS and b1-integrin expression, and reduced expression of inflammatory cytokines
and apoptosis. Our findings show that EPO and FN have an additive effect on wound repair in diabetic
mice.
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INTRODUCTION
Skin wound repair is a complex and fragile interplay between
cellular and biochemical events that take place in a closely
orchestrated cascade (Stadelmann et al., 1998). It consists of
four overlapping phases: hemostasis, inflammation, prolifera-
tion, and remodeling (Quinn, 1998; Stadelmann et al., 1998),
and is immediately set in motion in response to tissue injury.
Under certain conditions, such as diabetes mellitus, this
process is disrupted or delayed, and nonhealing, chronic
wounds develop (Clark, 1985; Brown et al., 1992; Shukla
et al., 1998; Mustoe, 2004). Such wounds often remain in the
inflammatory stage for a long time because of excessive
release of macrophage-induced proinflammatory cytokines
such as IL-1b, IL-6, and tumor necrosis factor-a (TNF-a;
Snyder, 2005). Diabetes also damages skin microvasculature
(Stadelmann et al., 1998; Sheetz and King, 2002), causes an
imbalance between the production and the degradation of
collagen, cytokines, and growth factors (Marhoffer et al.,
1992; Beer et al., 1997), and inhibits fibroblast proliferation
(Hehenberger et al., 1999) and wound re-epithelization by
keratinocytes (Mansbridge et al., 1999).
Fibronectin (FN), a high-molecular-weight glycoprotein,
has a critical role throughout the process of wound healing
(Pankov and Yamada, 2002). It has a soluble dimeric form in
the plasma and a cell-derived multimeric insoluble form in
the ECM. Plasma FN contributes to hemostasis and to the
control of infection, and enhances epithelialization and
organization of granulation tissue (Grinnell, 1984), but it is
degraded in diabetic wound tissues (Labat-Robert et al.,
1984; Wysocki and Grinnell, 1990). Topical treatment with
plasma FN improved diabetic wound healing in rats by
increasing fibroblast activity and tumor growth factor-b1
release (Qiu et al., 2007).
Erythropoietin (EPO) is a glycoprotein hormone that
regulates red blood cell mass. EPO targets nonhematopoietic
cells in the skin (Anagnostou et al., 1990; Haroon et al.,
2003; Isogai et al., 2006; Bodo et al., 2007) and can regu-
late wound healing. Systemically administered EPO may
contribute to the regulation of wound healing responses
through multiple mechanisms, including stimulation of vas-
cular endothelial growth factor (VEGF)-induced angiogenesis,
upregulation of inducible nitric oxide synthase (NOS) and
endothelial NOS (eNOS), increase in collagen synthesis and
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granulation tissue thickness, and decrease in inflammation
and the extent of cell apoptosis in the wound bed (Haroon
et al., 2003; Buemi et al., 2002, 2004; Galeano et al., 2004,
2006; Sayan et al., 2006; Sorg et al., 2009). Recently, we
confirmed that topical EPO treatment promoted wound repair
in diabetic rats (Hamed et al., 2010).
This study investigated if a combined topical treatment of
EPO and FN (EPO/FN) would have a greater effect than EPO
alone on repair of excisional skin wounds in a diabetes
mellitus type 1 hairless mouse model.
RESULTS
All mice in this study completed the treatment period.
Topical treatment of the wound with the vehicle-, EPO-, FN-,
or EPO/FN-containing creams did not change red blood cell,
leukocyte, and platelet counts, the elevated blood glucose
levels in the diabetic mice, or the hemoglobin levels of the
nondiabetic and diabetic mice (Table 1). The concentrations
of EPO and FN in plasma and wound tissues are shown in
Table 1.
Effect of EPO and FN on the rate of wound closure
Wounds of diabetic mice treated with vehicle-containing
cream exhibited a significantly slower healing rate than those
of healthy mice (Figure 1a). The most significant differences
in wound closure between the vehicle- and EPO/FN-treated
diabetic wounds were detected from day 4 onward (Figure
1b). From day 2 onward, the areas of the EPO/FN-treated
open wounds were significantly smaller than those of the
vehicle-, EPO-, and FN-treated wounds. From day 6 onward,
the areas of the EPO- and FN-treated diabetic wounds were
significantly different from the vehicle-treated diabetic
wounds. Comparisons between the areas of the EPO- and
FN-treated open wounds showed significant differences on
days 8–12 (Figure 1b).
Effects of EPO and FN on microvascular density (MVD),
wound VEGF, and hydroxyproline (HP) contents
After 6 and 12 days, the vehicle-treated diabetic wounds had
significantly lower MVD, VEGF, and HP content compared
with the vehicle-treated nondiabetic wounds (Figure 2c–, left;
Supplementary Figure S1c–e, left online). In the diabetic
mice, the MVD of the EPO/FN-treated wounds was sig-
nificantly higher than that of the EPO-treated wounds. The
MVD of the FN-treated wounds was significantly lower than
that of the EPO-treated wounds but not different than that of
the vehicle-treated wounds (Figure 2c, right; Supplementary
Figure S1c, right online). Treatment with EPO or EPO/FN, but
not with FN, significantly increased tissue VEGF content
(Figure 2d, right; Supplementary Figure S1d, right online).
EPO, FN, or EPO/FN significantly increased tissue HP content
of the diabetic wounds (Figure 2e, right; Supplementary
Figure S1e, right online).
Effect of EPO and FN on inflammatory cytokines in the wounds
After 6 and 12 days, the number of infiltrated macrophages
in vehicle-treated nondiabetic wounds was lower than that
of vehicle-treated diabetic wounds. No differences were
observed in the number of infiltrated macrophages in diabetic
wounds among the four treatment groups (Figure 3a–c;
Supplementary Figure S2a online). Diabetic wound tissues
treated with vehicle had significantly higher levels of IL-1b,
IL-6, and TNF-a compared with vehicle-treated nondiabetic
wound tissues. EPO and EPO/FN significantly decreased
IL-1b, IL-6, and TNF-a levels in diabetic wounds compared
with vehicle- and FN-treated diabetic wounds (Figure 3d;
Supplementary Figure S2b online).
Effect of EPO and FN on eNOS, b1-integrin, and apoptosis in
diabetic mice
After 6 and 12 days, EPO or EPO/FN significantly increased
the expression levels of eNOS and b1-integrin. FN signifi-
cantly increased b1-integrin levels, but not eNOS levels,
compared with vehicle. The b1-integrin levels in the EPO/FN-
treated wounds, but not the eNOS levels, were significantly
higher compared with those in the EPO-treated wounds
(Figure 4a and b; Supplementary Figure S3 online). In the
diabetic wounds, EPO and EPO/FN significantly reduced the
expression levels of the apoptotic proteins caspase 3 (casp-3)
and cytochrome c (cyt-c) compared with vehicle and FN
(Figure 4c and d; Supplementary Figure S3 online). After 6
days, TUNEL assay revealed significantly lower levels of
apoptotic cells in the EPO- and EPO/FN-treated wounds
compared with those in the vehicle- or FN-treated wounds
(Figure 4e and f).
EPO increases proliferation of glucose-stressed human
dermal microvascular endothelial cells (HDMECs) and
donor neonatal human foreskin cells (NHFCs)
Treatment with high glucose concentrations significantly
decreased the proliferation of both HDNECs (Figure 5a) and
NHFCs (Figure 5b). Treatment of glucose-stressed HDNECs
and NHFCs with EPO normalized their proliferation.
FN potentiates EPO effects on fibrin-adhered HDMECs and
NHFCs
EPO and FN significantly increased both the adherence of
NHFCs to fibrin and HP production by these cells. The
highest adherence levels and the highest HP levels were
observed in EPO/FN-treated NHFCs cultured on fibrin-coated
plates. Treatment of FN- or EPO/FN-treated NHFCs with the
tripeptide FN inhibitor RGD (arg-gly-asp) decreased the HP
levels produced by these cells and reduced their adherence
capacity compared with the adherence capacity of non-
treated and EPO-treated NHFCs cultured on fibrin- and
noncoated plates, respectively (Figure 5c and d).
HDMEC tube formation on fibrin-coated plates was
significantly higher compared with tube formation on non-
coated plates. EPO, FN, and EPO/FN significantly increased
HDMEC tube formation on fibrin-coated plates compared
with untreated cells. The highest levels of tube formation
were observed in EPO/FN-treated HDMECs cultured on
fibrin-coated plates. RGD decreased tube formation by
FN- and EPO/FN-treated HDMECs compared with tube
formation by nontreated and EPO-treated HDMECs cultured
on both fibrin- and noncoated plates, respectively (Figure 5e).
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DISCUSSION
We previously showed in diabetic rats that topical EPO
treatment of open wounds resulted in substantially smaller
wound areas compared with vehicle-treated wounds, without
changing the hematology profile of the animals (Hamed
et al., 2010). In this study we added FN to the treatment
of diabetic wounds because FN: (1) has a critical role
throughout the process of wound healing, (2) is deficient in
wound tissues of diabetic patients (Labat-Robert et al., 1984),
and (3) can improve the healing of diabetic wounds (Qiu
et al., 2007). Topical treatment of full-thickness diabetic
wounds with EPO/FN accelerated wound closure markedly,
indicating that FN can potentiate EPO-mediated wound
repair.
Wound models in animals demonstrated that angiogen-
esis, collagen disposition, secretion of growth factors, and
reduction in the inflammatory response were among the
underlying mechanisms of either systemic or topical EPO
treatment (Buemi et al., 2002, 2004; Galeano et al., 2004,
2006; Erbayraktar et al., 2009; Sorg et al., 2009; Hamed
et al., 2010). Increasing evidence suggests that EPO has an
indirect role as an angiogenic factor by stimulating the
production of VEGF and the expression of VEGF receptors
(Alvarez-Arroyo et al., 1998; Nakano et al., 2007; Westen-
brink et al., 2007; Wang et al., 2008). In the wound bed,
EPO-dependent VEGF-induced angiogenesis is still poorly
understood. This indirect action of EPO might be attributed to
its effect on stimulating the phosphatidylinositol 3-kinase/
AKT cellular pathway that is responsible in part for VEGF
secretion from either dermal endothelial cells or from
fibroblasts.
Diabetes mellitus leads to an increase in inflammation
and serum levels of proinflammatory cytokines such as
TNF-a (Doupis et al., 2010). In response to injury, a
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Figure 1. Wound closure. (a) Comparison between the time course of wound healing of healthy and diabetic mice treated with vehicle and (b) diabetic
mice treated with vehicle, EPO, FN, or EPO/FN. (c) Typical healthy and diabetic wounds after 12 days of treatment. (d) The black area represents the
surface of the wound area. (e) Time course of wound healing in diabetic mice that were treated with vehicle and (f) with EPO/FN. *Po0.05 and **Po0.001;
vehicle-treated wounds of the healthy mice versus diabetic mice, and for EPO-, FN-, or EPO/FN-treated wounds versus vehicle-treated wounds of diabetic mice.
wPo0.05; for EPO- versus FN-treated wounds. Abbreviations: D, diabetic mice; d, day; EPO, erythropoietin; EPO/FN, combination of erythropoietin and
fibronectin; FN, fibronectin; H, healthy mice.
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positive-feedback inflammatory cascade localizes around the
wound. Although proinflammatory cytokines enhance migra-
tion and division of cells involved in the proliferative phase,
they can become destructive by inducing cell apoptosis if
they persist in the wound bed, as occurs in chronic diabetic
wounds that often remain in the inflammatory stage for
protracted periods (Falanga, 2005). Brines and Cerami
(2008; see also Brines, 2010) suggested that endogenous
EPO may be produced locally in the immediate surrounding
area of an injured tissue to reduce cell apoptosis by inhibiting
the activity of inflammatory cells and suppressing proin-
flammatory cytokine production including TNF-a. Some
studies on human leukocytes and monocyte–macrophage
cell lines showed that EPO was able to inhibit the production
of proinflammatory cytokines including IL-2, -6, and -8, IFN-
g, and TNF-a (Strunk et al., 2008; Yazihan et al., 2008).
Various animal wound healing models demonstrated that the
reduction in inflammatory response in the wound bed was
among the significant underlying mechanisms of enhanced
wound repair in systemically EPO-treated animals (Buemi
et al., 2002; Kim and Hong, 2007). In this study we
demonstrated that topical EPO, but not topical FN treatment,
was associated with reduced levels of the proinflammatory
cytokines IL-1b, IL-6, and TNF-a without changing the
number of inflammatory cells (macrophages) in the diabetic
wound beds, implying a modulatory effect on the activity of
inflammatory cells rather than on their numbers. Previously,
we and others showed that EPO can inhibit apoptosis by
either upregulating the expression of antiapoptotic proteins
such as Bcl-XL (B-cell lymphoma-extra large) or by down-
regulating apoptotic proteins (Li et al., 2004; Hamed et al.,
2010). In this study, the low proinflammatory cytokine levels
observed in the diabetic wound beds were associated with
reduced apoptosis and reduced expression of casp-3 and cyt-
c. Increased inflammation and increased apoptosis, whether
it is associated with or independent of the inflammatory
response, may lead to a disruption in granulation tissue
formation and re-epithelialization. Accordingly, we propose
that topical EPO can prevent this by inhibiting proinflamma-
tory cytokine-mediated apoptosis, thereby providing cyto-
protection, or by inducing cell growth and proliferation.
Together with optimal provisional matrix (PM) formation
facilitated by exogenous FN, we assume that diabetic wounds
might re-epithelialize faster and more appropriately.
Essential for granulation tissue formation during the
proliferative phase of wound healing, FN and fibrin form
the PM that supports macrophages, fibroblasts, and angio-
genesis (Stadelmann et al., 1998). The PM allows intact
formation of granulation tissue and enables re-epithelializa-
tion and wound closure (Martin, 1997). In diabetes,
deficiency in FN and/or its degradation by proteases due to
inflammation lead to degradation of the PM, and epithelia-
lization does not occur or is delayed. Our results and those of
Qiu et al. (2007) show that topical FN treatment can improve
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cream, and (b) of wounds in diabetic mice treated with creams containing erythropoietin (EPO; upper), fibronectin (FN; middle), and a combination
of erythropoietin and fibronectin (EPO/FN; lower). Each arrow points to a newly formed blood vessel. Scale bar¼ 200mm. (c) MVD, (d) VEGF content,
and (e) hydroxyproline (HP) content in the wound beds after 6 days of topical treatment. *Po0.05, **Po0.001; EPO/FN versus vehicle, wwPo0.001;
EPO/FN versus EPO or FN, KPo0.001; FN versus EPO, and 1Po0.001; FN versus vehicle in diabetic mice.
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diabetic wound repair. Treatment with EPO/FN resulted in
enhanced endothelial tube formation and fibroblast adhe-
sion, and in increased collagen formation on fibrin-coated
wells in vitro, confirming that FN is essential for fibrin-
mediated PM formation and implying that FN can potentiate
EPO-mediated angiogenesis and collagen synthesis. As we
demonstrated in this study, topical treatment of diabetic
wounds with EPO/FN resulted in markedly better wound
healing than each treatment alone. Our findings are in line
with previous studies (Haroon et al., 2003; Galeano et al.,
2006). The newly formed granulation tissue and the
enhanced re-epithelialization were associated with increased
angiogenesis, an increase in macrophage and fibroblast
numbers, and in inducible nitric oxide synthase and eNOS
protein expression. We also demonstrated that EPO can
rescue both glucose-stressed endothelial and fibroblast
proliferation and the expression of eNOS and b1-integrin,
both in vitro (data not shown) and in vivo, in diabetic
wounds. EPO-induced eNOS expression in the wound
bed may indicate the presence of functional blood vessels
and may imply better blood flow. EPO- or FN-induced
b1-integrin expression in the wound bed may account
for enhanced matrix networking that has an important
role in granulation tissue formation and subsequently in
organized tissue regeneration. Collectively, these findings
can explain the additive effect of EPO and FN on diabetic
wound repair.
To the best of our knowledge, the results of this study
demonstrating an additive effect of topical treatment with
EPO and FN on skin wound repair in diabetic animals are
previously unreported. Topical treatment with EPO/FN was
not associated with any hematological changes and pro-
moted wound repair by affecting several stages of the healing
process and involving multiple mechanisms. We next
propose to evaluate the safety and efficacy of this topical
combination treatment in human diabetic patients.
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Figure 3. Inflammatory response in the wound bed. Representative micrographs of (a) newly formed skin in a healthy mouse (left) and a diabetic mouse
(right) after 6 days of topical treatment with the vehicle-containing cream, and (b) of wounds in diabetic mice treated with creams containing erythropoietin
(EPO; left), fibronectin (FN; middle), and a combination of erythropoietin and fibronectin (EPO/FN; right). Black arrows point to newly formed blood vessels
and white arrows point to CD68-positive cells. Scale bar¼ 400mm. The effect of topical treatments on (c) the number of CD68-positive cells (macrophages)
in wound tissues after 6 days and (d) proinflammatory cytokines. Each bar represents the mean pooled level of each proinflammatory cytokine in wound
tissues. **Po0.01; EPO or EPO/FN versus vehicle or FN in the diabetic mice.
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MATERIALS AND METHODS
Animals
All experimental procedures were reviewed and approved by the
Technion animal care and use committee. A total of 100 8-week-old
female hairless mice (Harlan, Jerusalem, Israel) were housed in cages
in a room with an artificial 12-h light/dark cycle. The mice were
acclimated for 1 week before the study, and had free access to
standard laboratory chow and water. Diabetes was induced in 80
mice by 6 intraperitoneal injections of 10mg kg–1 of streptozotocin
(Sigma Aldrich, St Louis, MO), which were repeated every 2 days.
At 10 days after the last streptozotocin injection, the blood glucose
level in a drop of tail blood from each streptozotocin-injected mouse
was measured by a glucometer (FreeStyle, Alameda, CA). Mice were
considered diabetic when their blood glucose levels were
4300mgdl–1. As the vehicle-treated nondiabetic control group, 20
apparently healthy mice were used.
Full-thickness skin wound preparation
Skin wounds were made in ketamine/xylazine-anesthetized mice. In
the diabetic mice, skin wounds were made 10 days after the last
streptozotocin injection, after hyperglycemia was confirmed. Once
anesthetized, the dorsal skin on each side of the vertebral column
was cleaned before creating two 4 cm2 full-thickness skin wounds
using an aseptic technique.
Preparation of wound treatment creams
The creams were prepared by a pharmacist according to the
recommendations in the United States Pharmacopoeia. The EPO-,
FN-, and EPO/FN-containing creams were prepared by mixing either
3,000 IU EPO (EPREX, Janssen Cilag, Bucks, UK) or 300 mgml–1 FN
(Millipore, Billerica, MA), or 3,000 IU EPO and 300mgml–1 FN with
1 g of powder containing 0.20% methyl paraben and 9% laureth/
isoparafin/polyacrylamide, and then dissolved in deionized water in
a final volume of 1ml. The stability of EPO or FN in the cream was
conserved after 1 month at 4 1C, as determined by ELISA.
Treatments
The 80 diabetic mice were divided randomly into four groups. Each
group was treated with 1ml of cream that contained: (1) vehicle
only; (2) 3,000 IUml–1 EPO; (3) 300mgml–1 FN; (4) 3,000 IU/ml–1
EPO and 300mgml–1 FN. The 20 nondiabetic control mice were
treated with vehicle only. The wounds were then covered with a
dressing film to prevent the cream from being removed, and to
protect the wound during self-grooming. Postoperative analgesics
and antibiotics were not administered because these drugs may
influence the healing process, and may therefore confound the
interpretation of the data. The mice in each group were divided
randomly into two subgroups of 10 mice each for two study-period
durations: 6 days and 12 days. Treatments and bandaging with the
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dressing film were repeated every 2 days for 6 and 12 days without
inducing anesthesia. At the beginning and at the end of each study
period, each mouse was weighed, and a blood sample was collected
for determining hemoglobin levels and red blood cell, leukocyte, and
platelet counts. EPO and FN levels in plasma and in the homogenates
of excised wound tissues were determined using ELISA (Quantikine
IVD Erythropoietin Kit, R&D Systems, MN; and Fibronectin AssayPro
Kit, Charles, MO), according to the manufacturers’ protocols.
Quantitative assessment of wound healing (wound closure)
Open wound size was determined on days 2, 4, 6, 8, 10, and 12 as
described previously (Hamed et al., 2010). After measuring the area
of the wound on day 6 or on day 12, the mice were killed humanely
with a ketamine/xylazine anesthetic overdose.
Histology and immunohistochemistry
On days 6 and 12, full-skin thickness samples of wound tissue from
all the dead animals were excised using a scalpel in order to avoid
damaging its healing edge, fixed immediately in 10% neutral buffered
formalin, and then embedded in paraffin. Immunohistochemistry was
performed using rabbit monoclonal antibodies against tissue CD31 (R&D
Systems) and CD68 (Dako, Glostrup, Denmark). The paraffin-embedded
sections were incubated with the antibodies overnight at room tempera-
ture. Upon completion of the incubation, the specimens were counter-
stained with hematoxylin. Mouse IgG was used as a negative control.
MVD was determined in wound tissues in regions of interest where
the CD31 antibody signal was the most intense. Infiltrated macrophages
were estimated by counting the number of CD68-positive cells in
wound tissues. Blood vessels and macrophages were counted (five fields
per specimen in all sections) under a light microscope at  200 and
 400 magnifications, respectively (N¼ 10 per group). TUNEL was used
for apoptotic cell detection. Briefly, sections were prepared according
to a previously described method (Jarvis et al., 2002), then incubated
with terminal deoxynucleotidyl transferase (TdT) reaction mix (98Uml–1
terminal transferase, 8mM biotinylated 16-dUTP in 10 TdT buffer; Roche
Diagnostic, Mannheim, Germany) for 90minutes at 37 1C, and then
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incubated for 30minutes with streptavidin–pox conjugate (Dako).
The specimens were counterstained with hematoxylin. Over 100
nuclei were counted for each slide (N¼ 10 per group) and the
percentage apoptosis in each section was calculated. Negative
controls were provided for each section under evaluation by
omitting the TdT enzyme from the TdT mix in the reaction. Positive
controls were established by treating a section with DNase 2mgml–1
(Roche Diagnostic) before incubation with TdT mix. All evaluations
were made by SH, EH, DE, and YU, who were blind to the treatment.
Determination of VEGF, collagen contents, and inflammatory
cytokines
Samples (100mg) of freshly excised wound tissue were collected
and homogenized on days 6 and 12. VEGF content was determined
using the Quantikine mouse VEGF immunoassay (R&D Systems),
and collagen contents was determined by HP levels, as previously
described (Hamed et al., 2010). IL-1b, IL-6, and TNF-a were deter-
mined using mouse Single Analyte ELISArray Kits (SABiosciences,
Frederick, MD) according to the manufacturer’s protocols. The
results for VEGF and HP were expressed as the mean of all samples
in each group (N¼ 10 per group). The results of the proinflammatory
cytokines were calculated from the mean of all samples in each
group (N¼ 10 per group), and expressed as the mean percentage
from vehicle-treated wounds of the nondiabetic mice.
Western blot
The expression levels of eNOS, b1-integrin, casp-3, and cyt-c on
days 6 and 12 were determined by western analysis. Briefly, samples
from excised wound tissues were homogenized in phosphate-buffered
saline (PBS) containing Complete Protease Inhibitor Cocktail (Sigma
Aldrich, St Louis, MO) and lysed in RIPA buffer (R&D Systems). From
each lysate, 40 mg aliquots were separated using SDS-PAGE and
transferred to nitrocellulose membranes, which were then incubated
with monoclonal antibodies against eNOS, b1-integrin, casp-3, and
cyt-c (Santa Cruz Biotechnology, Santa Cruz, CA), and with a
horseradish peroxidase-conjugated IgG secondary antibody (Santa
Cruz Biotechnology). b-Actin was used to normalize protein loading.
The resultant bands were quantified by densitometry for each wound
bed in the vehicle-treated nondiabetic wounds and in the vehicle-,
EPO-, FN-, and EPO/FN-treated diabetic wounds (N¼ 10 per group).
The results were expressed as the average of mean percentage of the
bands from the vehicle-treated wounds of nondiabetic mice.
Cell cultures
Primary adult HDMECs derived from adult dermis, and primary
NHFCs derived from neonatal donor foreskin (Cell Systems,
Kirkland, WA) were propagated on type 1 collagen-coated flasks
in the recommended CSC media (Cell Systems) supplemented with
10% fetal bovine serum, 100Uml–1 penicillin, 100 mgml–1 strepto-
mycin, and 2mgml–1 amphotericin, and used at passages 4–6 in two
different protocols as described below.
Protocol 1: assessment of the effects of high glucose levels
and EPO treatment on the proliferation of HDMECs and
NHFCs. The cells were harvested, replated (B100,000 cells per
well) on type 1 collagen-coated 24-well plates in CSC media with
10% fetal bovine serum, and exposed to 30mmolml–1 D-glucose
(high glucose concentration) for 5 days, with or without EPO
treatment (100 IUml–1), in a humidified incubator with 5% CO2 at
37 1C. After 5 days, HDMECs and NHFC proliferation was measured
using an MTT assay (Sigma) according to the manufacturer’s
protocol. Protein extracts were prepared from both cell types to
assess the expression levels of eNOS, b1-integrin, casp-3, and cyt-c
using western analysis as described above.
Protocol 2: the effect of treatment with EPO and FN on tube
formation, angiogenic ability, and adherence to fibrin. The
harvested HDMECs and NHFCs were replated on fibrin-coated 24-
well plates in CSC media with 10% fetal bovine serum at a density of
B50,000 cells per well, and incubated with 100 IUml–1 EPO, or
100mgml–1 FN, or with a combination of EPO (100 IUml–1) and FN
(100mgml–1). HDMECs were maintained for 12 hours, and NHFCs
were maintained for 2 hours in a humidified incubator with 5% CO2
at 37 1C. RGD (10 ngml–1; Santa Cruz Biotechnology) was used to
neutralize FN. The angiogenic ability of HDMECs was assessed by
VEGF levels in conditioned media from these cells using the
Quantikine human VEGF ELISA immunoassay (R&D Systems). The
ability of NHFCs to produce collagen was assessed by their
adherence to fibrin and by the levels of HP produced by the cells
in conditioned media, as previously described (Hamed et al., 2010).
Tube formation assay
After 12 hours, the nonintegrated HDMECs were removed by gentle
washing with PBS and tube formation on fibrin was assessed under a
light microscope at  10 magnification. The tubular structures were
graded semiquantitatively by evaluating the presence and stages of
tube formation on a scale of 0 to 5, where: 0¼well-separated
individual cells, 1¼ cells had begun to migrate and align them-
selves, 2¼ visible capillary tubes and no sprouting, 3¼ visible
sprouting of new capillary tubes, 4¼ early formation of closed
polygons, and 5¼ development of complex mesh-like structures. All
evaluations were assessed by two investigators who were blinded to
the treatments. Four random high-power fields in each sample in
duplicates from three independent experiments were examined. The
results from each evaluator were then pooled in order to calculate
the mean value for each criterion for each sample in each treatment.
Adhesion assay
After 2hours of incubation, the NHFCs that did not adhere to fibrin
were removed by washing with PBS. The remaining adhered cells were
fixed with 1% glutaraldehyde in distilled water for 20minutes at room
temperature. The plate was washed gently with PBS, and 100ml of
0.1% crystal violet in 0.2M boric acid was added to each well for
20minutes. Excess stain was removed by washing with PBS. Stained
cells were air-dried before the crystal violet was solubilized by 10%
acetic acid. Cell adherence was quantified in duplicates from three
independent experiments by measuring the absorbance at 590nm with
a dual-wavelength microplate reader, and the reading was corrected for
light scattering by subtraction of the absorbance at 450nm.
Statistical analysis of the data
The data for each study parameter from the vehicle-, EPO-, FN-, and
EPO/FN-treated wound tissues for each group were pooled, and the
results are presented as mean±SD. The data had normal distribution
by Kolmogorov–Smirnov test. The data from each group were
statistically analyzed by one-way analysis of variance using a
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computerized statistical program (Prism version 5.0, GraphPad
Software, La Jolla, CA). Differences were considered statistically
significant when Pp0.05.
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